Skip to main content
TipRanks
Go Ultimate75% OFF

Entera Bio (5DT) Stock Price & Analysis

0 Followers

5DT Stock Chart & Stats

€2.86€0.06(2.14%)
At close: 5:30 PM GMT+1
€2€2.5€3€3.5Jul 31Aug 12Sep 4Sep 30
Day’s Range
EUR 2.86 - EUR 2.86
52-Week Range
EUR 0.84 - EUR 3.46
Previous Close
EUR 2.80
Volume
N/A
Average Volume (3M)
0
Market Cap
EUR 491.28M
Enterprise Value
EUR 150.15M
Total Cash (Recent Filing)
EUR 265.88M
Total Debt (Recent Filing)
EUR 397.00K
Price to Earnings (P/E)
―
Beta
0.68
Next Earnings
Mar 26, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

Very low leverage gives Entera substantial balance-sheet flexibility relative to its development-stage operations. The reported equity and asset base can support continued clinical investment and reduce near-term debt-service pressure, although the company still must convert capital into durable operating progress.

EB613 Phase 3 Readiness

Regulatory alignment on a defined Phase 3 design materially advances EB613 toward a pivotal development milestone. A clear trial path can focus resources, improve execution planning, and establish a stronger basis for evaluating the oral osteoporosis candidate over the next several quarters.

Broad Oral Peptide Pipeline

Multiple programs extend the value of Entera’s oral peptide platform beyond one asset. Progress in hypoparathyroidism and metabolic disease creates additional clinical catalysts and diversification, while the OPKO collaboration provides a structured route for advancing EB612 toward human studies.

Bears Say

Minimal Revenue And Persistent Losses

Entera has not established recurring product revenue, and substantial operating losses continue despite the recent TTM net-income improvement. This leaves results dependent on development progress and non-operating items rather than a proven commercial engine, limiting earnings durability over the medium term.

Ongoing Cash Burn

Persistent negative operating cash flow shows that Entera’s research programs have not yet become self-funding. Although TTM cash flow is near break-even, the pack describes it as volatile and not supported by durable operating profitability, leaving future development reliant on available capital.

External Funding Dependence

Because Entera lacks an approved commercial product, advancing its pipeline depends on cash reserves, collaborations, or additional financing rather than recurring sales. This capital-dependent model can make long-term execution sensitive to funding needs, while higher R&D spending increases the resources required.

Entera Bio News

5DT FAQ

What was Entera Bio’s price range in the past 12 months?
Entera Bio lowest stock price was €0.84 and its highest was €3.46 in the past 12 months.
What is Entera Bio’s market cap?
Entera Bio’s market cap is €491.28M.
When is Entera Bio’s upcoming earnings report date?
Entera Bio’s next earnings report is estimated for Mar 26, 2027 (not yet confirmed), which is in 131 days.
How were Entera Bio’s earnings last quarter?
Entera Bio released its earnings results on Nov 06, 2026. The company reported -€0.098 earnings per share for the quarter, missing the consensus estimate of -€0.058 by -€0.04.
Is Entera Bio overvalued?
According to Wall Street analysts Entera Bio’s price is currently Undervalued.
Does Entera Bio pay dividends?
Entera Bio does not currently pay dividends.
What is Entera Bio’s EPS estimate?
Entera Bio’s EPS estimate is -0.15.
How many shares outstanding does Entera Bio have?
Entera Bio has 174,137,770 shares outstanding.
What happened to Entera Bio’s price movement after its last earnings report?
Entera Bio reported an EPS of -€0.098 in its last earnings report, missing expectations of -€0.058. Following the earnings report the stock price went up 5.385%.
Which hedge fund is a major shareholder of Entera Bio?
Currently, no hedge funds are holding shares in DE:5DT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology